One in ten mothers will experience persistent sadness, lack of energy, and difficulty bonding with their baby in the first year after birth. These conditions can eventually lead to a mental health disorder such as postpartum depression. Although it can be treated with psychological and psychiatric therapy, as well as hospitalization in severe cases, there are no specific pharmacological therapies in Europe, and the available options—antidepressants and serotonin reuptake inhibitors—are too generic and take too long to work. However, in the United States, for two years now, you can access the Zurzuvae, a pill that is estimated to halve the symptoms associated with the disorder. This Wednesday, the European Commission authorized its marketing.